Related Experiment Videos

Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK

Lynn T Singer1, Derek G Moore2, Meeyoung O Min1

  • 1Case Western Reserve University, Cleveland, Ohio, USA.

Insights

Prenatal exposure to methylenedioxymethamphetamine (MDMA, "ecstasy") is linked to motor delays in infants. Higher MDMA exposure correlated with greater motor deficits up to 12 months.

Area of Science:

  • Developmental Pediatrics
  • Neuroscience
  • Obstetrics

Background:

  • Prenatal exposure to recreational drugs, including methylenedioxymethamphetamine (MDMA, "ecstasy"), may impact infant development.
  • Understanding the long-term effects of prenatal MDMA exposure is crucial for public health and clinical guidance.

Purpose of the Study:

  • To examine the effects of prenatal methylenedioxymethamphetamine (MDMA) exposure on infant development from birth to two years.
  • To investigate the relationship between the amount of MDMA exposure and developmental outcomes.

Main Methods:

  • A prospective, longitudinal cohort study followed 28 MDMA-exposed and 68 non-exposed infants.
  • Maternal interviews collected data on drug use during pregnancy, controlling for covariates.
  • Infants underwent standardized developmental assessments at 1, 4, 12, 18, and 24 months.

Main Results:

  • No significant differences were observed at birth, though MDMA-exposed infants were more likely to be male.
  • Motor delays were consistently observed in MDMA-exposed infants.
  • A dose-dependent relationship was found between MDMA exposure and motor deficits at 12 months.

Conclusions:

  • Prenatal MDMA exposure is associated with fine and gross motor delays in early childhood.
  • Further research is necessary to ascertain the long-term developmental consequences of prenatal MDMA exposure.
Abstract

Related Concept Videos